|
|
Product Pipeline Descriptions
The information below provides some additional information about the products in CSL's product pipeline. This is a brief overview of the product. Information is organised according to its place in the pipeline.
Research/Pre-Clinical Market DevelopmentFibrinogen
New Indications | Research and pre-clinical studies to seek additional medical use for Fibrinogen concentrate. | PCC
New Indications | Research and pre-clinical studies to seek additional medical use for Prothrombin complex concentrate. |
New Product Development Novel Plasma
Proteins | Identification of novel therapeutic uses for plasma proteins. | | Recombinant Coagulation Factors | Research activities to develop novel strategies for recombinant coagulation factors. | | CSL689 rVIIa-FP | Recombinant coagulation factor VIIa with extended half-life. | | rvWF-FP | | | Partnered Vaccine Programs* | | P.Gingivalis/POD
CRC-OHS/Sanofi | Vaccine to prevent and treat the severe gum disease Periodontitis, caused by the bacterium Porphyromonas gingivalis. | | CSL362 IL-3R | Recombinant Monoclonal Antibody against the IL-3 Receptor for the potential treatment of acute myeloid leukaemia. | | Discovery Projects | Research projects aiming to develop recombinant therapeutic proteins, particularly monoclonal antibodies. | | CSL324 G-CSFR | Recombinant Monoclonal Antibody against the cytokine granulocyte colony stimulating factor for the potential development of a new class of drugs that targets arthritis and other inflammatory diseases. | | VEGFB | |
Clinical Development
Market Development
| Privigen® CIDP EU | A Phase III study in Europe of Privigen in CIDP (Chronic Inflammatory Demyelinating Polyneuropathy). | Fibrinogen
Aortic Surgery | Clinical studies testing the use of Fibrinogen concentrate as a quickly administered, fast acting, low volume medicine to microvascular bleeding to reduce the need for donated (allogenic) blood products. | | Zemaira® EU | Alpha1 - Proteinase Inhibitor in subjects with emphysema due to A1PI deficiency. | | Beriplex® US | Two phase III trials to demonstrate use of Beriplex (plasma derived concentrate of coagulation factors II, VII, IX and X) in patients with acquired deficiency of coagulation factors. |
New Product Development
| CSL654 rIX-FP | Recombinant coagulation factor IX with extended half-life. A Phase I study in subjects with haemophilia B has commenced. | | CSL627 rFVIII | A unique single chain recombinant factor VIII (rFVIII) for treatment of Haemophilia A will soon enter Phase I clinical testing. | | Partnered Vaccine Programs | | | CAM3001 GM-CSFR -AZ* | Recombinant monoclonal antibody inhibiting GM-CSF activity by targeting the GM-CSF receptor for use in rheumatoid arthritis. Licensed to Astra Zeneca. Successfully completed a Phase II clinical trial in 2011. | | CSL112 reconstituted HDL | Reconstituted high density lipoprotein (rHDL) for secondary treatment in acute coronary syndrome; rHDL is made from apoA1 lipoprotein isolated from human plasma then reconstituted with lipid. |
Registration/Post Launch
Life Cycle Management| Specialty Products | | | Haemophilia | | | Immunoglobulins | | | Influenza Vaccines | Seasonal influenza vaccine. |
Market Development
| Hizentra® US | 20% subcutaneous immunoglobulin for treatment of primary immune deficiency (PID) | | Hizentra® EU | | | Berinert® Self Admin | C1 Esterase Inhibitor for subjects with congenital deficiency and acute abdominal and facial HAE attacks. Approved in US and Europe. | | Riastap® EU | Fibrinogen concentrate in Phase IV clinical studies in subjects with congenital fibrinogen deficiency. | | FXIII US | | | Biostate® EU | |
|